Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Emodepside for Trichuris trichiura and hookworm infection
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4683471
Author(s) Mrimi, E. C.; Welsche, S.; Ali, S. M.; Hattendorf, J.; Keiser, J.
Author(s) at UniBasel Mrimi, Emmanuel
Welsche, Sophie
Hattendorf, Jan
Keiser, Jennifer
Year 2023
Title Emodepside for Trichuris trichiura and hookworm infection
Journal The New England journal of medicine
Volume 388
Number 20
Pages / Article-Number 1863-1875
Mesh terms Adult; Animals; Humans; Albendazole, therapeutic use; Feces, parasitology; Hookworm Infections, drug therapy; Soil, parasitology; Trichuriasis, drug therapy; Trichuris; Depsipeptides, therapeutic use; Antinematodal Agents, therapeutic use; Young Adult; Middle Aged; Administration, Oral; Dose-Response Relationship, Drug
Abstract BACKGROUND: Current treatments for soil-transmitted helminth infections in humans have low efficacy against Trichuris trichiura. Emodepside - a drug in veterinary use and under development for the treatment of onchocerciasis in humans - is a leading therapeutic candidate for soil-transmitted helminth infection. METHODS: We conducted two phase 2a, dose-ranging, randomized, controlled trials to evaluate the efficacy and safety of emodepside against T. trichiura and hookworm infections. We randomly assigned, in equal numbers, adults 18 to 45 years of age in whom T. trichiura or hookworm eggs had been detected in stool samples to receive emodepside, at a single oral dose of 5, 10, 15, 20, 25, or 30 mg; albendazole, at a single oral dose of 400 mg; or placebo. The primary outcome was the percentage of participants who were cured of T. trichiura or hookworm infection (the cure rate) with emodepside 14 to 21 days after treatment, determined with the use of the Kato-Katz thick-smear technique. Safety was assessed 3, 24, and 48 hours after the receipt of treatment or placebo. RESULTS: A total of 266 persons were enrolled in the T. trichiura trial and 176 in the hookworm trial. The predicted cure rate against T. trichiura in the 5-mg emodepside group (85% [95% confidence interval CI, 69 to 93]; 25 of 30 participants) was higher than the predicted cure rate in the placebo group (10% [95% CI, 3 to 26]; 3 of 31 participants) and the observed cure rate in the albendazole group (17% [95% CI, 6 to 35]; 5 of 30 participants). A dose-dependent relationship was shown in participants with hookworm: the observed cure rate was 32% (95% CI, 13 to 57; 6 of 19 participants) in the 5-mg emodepside group and 95% (95% CI, 74 to 99.9; 18 of 19 participants) in the 30-mg emodepside group; the observed cure rates were 14% (95% CI, 3 to 36; 3 of 21 participants) in the placebo group and 70% (95% CI, 46 to 88; 14 of 20 participants) in the albendazole group. In the emodepside groups, headache, blurred vision, and dizziness were the most commonly reported adverse events 3 and 24 hours after treatment; the incidence of events generally increased in a dose-dependent fashion. Most adverse events were mild in severity and were self-limited; there were few moderate and no serious adverse events. CONCLUSIONS: Emodepside showed activity against T. trichiura and hookworm infections. (Funded by the European Research Council; ClinicalTrials.gov number, NCT05017194.).
ISSN/ISBN 0028-4793
edoc-URL https://edoc.unibas.ch/94893/
Full Text on edoc No
Digital Object Identifier DOI 10.1056/NEJMoa2212825
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/37195942
ISI-Number MEDLINE:37195942
Document type (ISI) Journal Article, Randomized Controlled Trial
 
   

MCSS v5.8 PRO. 0.324 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
20/06/2024